Some of the cutaneous adverse events to amivantamab, which targets both EGFR and MET, can be severe and have atypical presentations, which led to dose reductions in five of six cases.
Fatigue and poor physical functioning before treatment, in particular, are associated with worse tolerance of chemotherapy among patients with early breast cancer.
For women with diffuse large B-cell lymphoma undergoing chemotherapy, survival was better with less toxicity when the drugs were administered in the afternoon than in the morning.
Over the last few years, physicians have experimented with taking patients with chronic myeloid leukemia (CML) off their drugs entirely, and the results are promising.